Study Introduction: This clinical investigation was meticulously designed to explore the efficacy of VERISOL® in the treatment of cellulite, addressing a common concern among women. The study focused on assessing VERISOL®'s ability to combat cellulite in both normal-weight and overweight women, providing valuable insights into its potential applications.
Study Design: Employing a rigorous double-blind, placebo-controlled trial, the study enrolled 105 women aged 24-50. The participants were divided into two subgroups based on BMI—those with BMI < 25 and those with BMI > 25. Each subgroup was subjected to a daily intake of 2.5g VERISOL® or a placebo. The duration of the trial extended over a significant period of 6 months.
Key Findings
- The results revealed promising outcomes in the reduction of cellulite-related indicators.
- Across the overall VERISOL® group, there was a significant decrease in skin waviness, registering an impressive -8% reduction.
- Moreover, the subgroup of women with normal weight (BMI < 25) experienced an even more notable improvement, with an -11% reduction in skin waviness.
- Notably, the study also identified a significantly higher dermal density after 6 months in the VERISOL® group compared to the placebo, highlighting the comprehensive benefits of VERISOL® in treating cellulite.
Conclusion: This comprehensive study, conducted over a 6-month duration, underscores VERISOL®’s potential as an effective treatment for cellulite, offering encouraging results in both normal-weight and overweight women.